GSK strikes deal to cut drug prices with US government GSK has struck a voluntary agreement with the US government to lower the cost of prescription medicines and expand access to treatments for millions of Americans. The move comes as pressure mounts on global drugmakers over pricing, tariffs, and domestic investment. The London-listed pharma giant said the deal covers medicines used by over 40m US [...]
Hikma: FTSE 100 giant’s boss replaced by former chief after share price woes pharma The boss of FTSE 100 giant Hikma Pharmaceuticals will be replaced by the firm’s former top chief after the group’s share price dropped by nearly a quarter this year. Riad Mishlawi has exited his role as chief executive at Hikma, with executive chairman Said Darwazah to step into the post with “immediate effect”. It ends [...]
UK and US agree to zero tariff deal on pharmaceuticals Business The government has agreed to a major deal with Washington that will see the UK become the only country to secure zero import tariffs on pharmaceutical products into the US for at least three years. The deal follows months of negotiations between the government and the Trump administration, after the June trade deal left the [...]
Astrazeneca injects $2bn to boost US manufacturing capabilities November 24, 2025 FTSE 100 giant Astrazeneca plans to invest $2bn into growing its manufacturing footprint in Maryland, as part of its efforts to boost its US capabilities and presence. The investment will support the “significant expansion” of its biologics manufacturing facility in Frederick, doubling its capacity and increasing its medicine supply, as well as the construction of [...]
GSK shares jump as profit upgrade defies tariff gloom October 29, 2025 Shares in GSK climbed as much as three per cent to 1,705p on Wednesday morning as the pharma giant defied tariff fears with an upgrade to its profit guidance. The London-based business said it now expects turnover to increase by six to seven per cent for the full year 2025, up from its previous guidance [...]
GSK shares rally as chief Emma Walmsley to exit after eight years September 29, 2025 The chief executive of pharmaceutical giant GSK has announced plans to step down from the company at the end of the year. Emma Walmsley, who took the helm of the drugmaker in 2017, will be replaced by chief commercial officer Luke Miels. Miels – the former Executive Vice President of Astrazeneca – also joined the [...]
Trump slaps 100 per cent tariff on imported drugs September 26, 2025 US President Donald Trump announced a new round of tariffs on Thursday evening, with the pharmaceutical industry expected to be the hardest hit. Trump revealed that the US will impose a 100 per cent tariff on imported branded drugs, a 25 per cent tariff on all heavy-duty truck imports, a 50 per cent tariff on [...]
Mounjaro sales help almost double Ely Lilly’s UK turnover September 18, 2025 The sale of weight loss drug Mounjaro has boosted the UK turnover of pharmaceuticals giant Eli Lilly by 90 per cent during its latest financial year, it has been revealed. The division of the US group has posted a turnover of £889m for 2024, according to new accounts filed with Companies House. The new total [...]
GSK plots $30bn investment into US in latest blow to UK’s pharma sector September 17, 2025 GSK has unveiled a new plan to spend $30bn (£22bn) on research and manufacturing facilities in the US. The London-based business said the capital would be deployed over the next five years and would create hundreds of high-skilled American jobs in areas such as AI and advanced digital technologies. The investment of £4.4bn per year [...]
Merck warns UK is ‘not internationally competitive’ as it scraps £1bn London research centre September 10, 2025 Merck has pulled out of a planned £1bn London drug research centre in the latest blow to the government’s growth agenda. The US pharma giant is to lay off 127 staff alongside abandoning the construction project, which had been set to open in King’s Cross in 2027. The firm warned the UK would lag behind [...]